ArchiMed, the healthcare specialist investor, is putting its MED IV fund, sized at 1.5 billion euros, about $1.75 billion, to work with artificial intelligence as a stated screening theme for healthcare deals, according to a PE Hub interview with founder Denis Ribon published this week.
The details available are limited: the interview sits behind a paywall, and no fund close announcement, deployment pace or named transactions were in the reporting accessible at write time. ArchiMed is a global healthcare investor founded in 2014, with offices in North America, Europe and Asia, and about 9.5 billion euros of assets under management across its fund family, per its own published materials.
What can be said on the record is the direction: a sector specialist of this size framing AI as a deployment filter for healthcare buyouts, rather than as a separate technology strategy, mirrors how generalist funds have begun underwriting AI exposure inside portfolio operations. The fund size figure is carried in PE Hub’s reporting in both euro and dollar form.
This story ships at grade C because its primary source is a single, paywalled trade interview. No deployment figures beyond the fund size are asserted.